Thromboembolic events in children and young adults with pediatric sarcoma

Journal of Clinical Oncology

Volumn 25, Issue 12, 2007, Pages 1519-1524

  Paz Priel, Ido ^a   Long, Lauren ^a   Helman, Lee J ^a   Mackall, Crystal L ^a   Wayne, Alan S ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; HEPARIN; IFOSFAMIDE; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; METHOTREXATE; VINCRISTINE; WARFARIN; ANTICOAGULANT AGENT;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG MEGADOSE; EWING SARCOMA; FATALITY; FEMALE; HUMAN; INTRAVENOUS CATHETER; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; METASTASIS; OSTEOSARCOMA; PREVALENCE; PRIORITY JOURNAL; RHABDOMYOSARCOMA; RISK FACTOR; SARCOMA; THROMBOSIS; VENOUS THROMBOEMBOLISM; AGE DISTRIBUTION; BONE TUMOR; COHORT ANALYSIS; COMORBIDITY; CONFIDENCE INTERVAL; CONNECTIVE TISSUE TUMOR; PATHOLOGY; PRESCHOOL CHILD; PROBABILITY; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEX RATIO; SURVIVAL; THROMBOEMBOLISM;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANTICOAGULANTS; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COMORBIDITY; CONFIDENCE INTERVALS; FEMALE; HUMANS; MALE; OSTEOSARCOMA; PREVALENCE; PROBABILITY; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SARCOMA; SARCOMA, SYNOVIAL; SEX DISTRIBUTION; SURVIVAL ANALYSIS; THROMBOEMBOLISM;

EID: 34248197473     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.06.9930     Document Type: Article

References (51)

1. Wiernikowski JT, Athale UH: Thromboembolic complications in children with cancer. Thromb Res 118:137-152, 2006
2. Athale UH, Chan AK: Thrombosis in children with acute lymphoblastic leukemia: Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia - Effects of the disease and therapy. Thromb Res 111:199-212, 2003
3. Blom JW, Doggen CJ, Osanto S, et al: Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293:715-722, 2005
4. Hettiarachchi RJ, Lok J, Prins MH, et al: Undiagnosed malignancy in patients with deep vein thrombosis: Incidence, risk indicators, and diagnosis. Cancer 83:180-185, 1998
5. Lee AY, Levine MN: Venous thromboembolism and cancer: Risks and outcomes. Circulation 107:117-121, 2003
6. Di Nisio M, Otten HM, Piccioli A, et al: Decision analysis for cancer screening in idiopathic venous thromboembolism. J Thromb Haemost 3:2391-2396, 2005
7. Monreal M, Lensing AW, Prins MH, et al: Screening for occult cancer in patients with acute deep vein thrombosis or pulmonary embolism. J Thromb Haemost 2:876-881, 2004
8. Piccioli A, Lensing AW, Prins MH, et al: Extensive screening for occult malignant disease in idiopathic venous thromboembolism: A prospective randomized clinical trial. J Thromb Haemost 2:884-889, 2004
9. Rance A, Emmerich J, Guedj C, et al: Occult cancer in patients with bilateral deep-vein thrombosis. Lancet 350:1448-1449, 1997
10. Rickles FR, Levine MN: Epidemiology of thrombosis in cancer. Acta Haematol 106:6-12, 2001
11. Saba HI, Khalil FK, Morelli GA, et al: Thromboembolism preceding cancer: A correlation study. Am J Hematol 72:109-114, 2003
12. Shen VS, Pollak EW: Fatal pulmonary embolism in cancer patients: Is heparin prophylaxis justified? South Med J 73:841-843, 1980
13. Sorensen HT, Mellemkjaer L, Steffensen FH, et al: The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 338:1169-1173, 1998
14. Sorensen HT, Mellemkjaer L, Olsen JH, et al: Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343:1846-1850, 2000
15. Prandoni P, Falanga A, Piccioli A: Cancer and venous thromboembolism. Lancet Oncol 6:401-410, 2005
16. Donati MB, Falanga A: Pathogenetic mechanisms of thrombosis in malignancy. Acta Haematol 106:18-24, 2001
17. Falanga A, Donati MB: Pathogenesis of thrombosis in patients with malignancy. Int J Hematol 73:137-144, 2001
18. Falanga A, Marchetti M, Vignoli A, et al: Clotting mechanisms and cancer: Implications in thrombus formation and tumor progression. Clin Adv Hematol Oncol 1:673-678, 2003
19. Levine MN, Gent M, Hirsh J, et al: The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 318:404-407, 1988
20. Monagle P, Adams M, Mahoney M, et al: Outcome of pediatric thromboembolic disease: A report from the Canadian Childhood Thrombophilia Registry. Pediatr Res 47:763-766, 2000
21. van Ommen CH, Heijboer H, van den Dool EJ, et al: Pediatric venous thromboembolic disease in one single center: Congenital prothrombotic disorders and the clinical outcome. J Thromb Haemost 1:2516-2522, 2003
22. Athale UH, Siciliano SA, Crowther M, et al: Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: Effect of age and risk stratification of disease. Br J Haematol 129:803-810, 2005
23. Mitchell LG, Andrew M, Hanna K, et al: A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: Results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. Cancer 97:508-516, 2003
24. Nowak-Gottl U, Ahlke E, Fleischhack G, et al: Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): Prednisone versus dexamethasone administration. Blood 101: 2529-2533, 2003
25. Cheruku R, Tapazoglou E, Ensley J, et al: The incidence and significance of thromboembolic complications in patients with high-grade gliomas. Cancer 68:2621-2624, 1991
26. Streiff MB, Segal J, Grossman SA, et al: ABO blood group is a potent risk factor for venous thromboembolism in patients with malignant gliomas. Cancer 100:1717-1723, 2004
27. Deitcher SR, Gajjar A, Kun L, et al: Clinically evident venous thromboembolic events in children with brain tumors. J Pediatr 145:848-850, 2004
28. Tabori U, Beni-Adani L, Dvir R, et al: Risk of venous thromboembolism in pediatric patients with brain tumors. Pediatr Blood Cancer 43:633-636, 2004
29. Athale U, Cox S, Siciliano S, et al: Thromboembolism in children with sarcoma. Pediatr Blood Cancer [epub ahead of print September 26, 2006]
30. Levine MN, Lee AY: Risk assessment and primary VTE prevention in the cancer patient. Pathophysiol Haemost Thromb 33:36-41, 2003 (suppl 1)
31. Mitchell L, Hoogendoorn H, Giles AR, et al: Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: Risk of thrombotic complications in L-asparaginase-induced antithrombin III deficiency. Blood 83:386-391, 1994
32. Silverman LB, Gelber RD, Dalton VK, et al: Improved outcome for children with acute lymphoblastic leukemia: Results of Dana-Farber Consortium Protocol 91-01. Blood 97:1211-1218, 2001
33. Feinberg WM, Swenson MR: Cerebrovascular complications of L-asparaginase therapy. Neurology 38:127-133, 1988
34. Ott N, Ramsay NK, Priest JR, et al: Sequelae of thrombotic or hemorrhagic complications following L-asparaginase therapy for childhood lymphoblastic leukemia. Am J Pediatr Hematol Oncol 10: 191-195, 1988
35. Priest JR, Ramsay NK, Steinherz PG, et al: A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia. J Pediatr 100:984-989, 1982
36. Korte W, Feldges A, Baumgartner C, et al: Increased thrombin generation during fibrinogen and platelet recovery as an explanation for hypercoagulability in children with L-asparaginase therapy for ALL or NHL: A preliminary report. Klin Padiatr 206:331-333, 1994
37. Sutor AH, Mall V, Thomas KB: Bleeding and thrombosis in children with acute lymphoblastic leukaemia, treated according to the ALL-BFM-90 protocol. Klin Padiatr 211:201-204, 1999
38. Athale UH, Chan AK: Thrombosis in children with acute lymphoblastic leukemia: Part III. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia - Effects of host environment. Thromb Res 111:321-327, 2003
39. Sifontes MT, Nuss R, Hunger SP, et al: The factor V Leiden mutation in children with cancer and thrombosis. Br J Haematol 96:484-489, 1997
40. Wermes C, von Depka Prondzinski M, Lichtinghagen R, et al: Clinical relevance of genetic risk factors for thrombosis in paediatric oncology patients with central venous catheters. Eur J Pediatr 158:S143-S146, 1999 (suppl 3)
41. Knofler R, Siegert E, Lauterbach I, et al: Clinical importance of prothrombotic risk factors in pediatric patients with malignancy: Impact of central venous lines. Eur J Pediatr 158:S147-S150, 1999 (suppl 3)
42. Nowak-Gottl U, Wermes C, Junker R, et al: Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood 93:1595-1599, 1999
43. Shi W, Krilis SA, Chong BH, et al: Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust N Z J Med 20:231-236, 1990
44. Vila P, Hernandez MC, Lopez-Fernandez MF, et al: Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost 72:209-213, 1994
45. Asherson RA: Antiphospholipid antibodies, malignancies and paraproteinemias. J Autoimmun 15:117-122, 2000
46. Lossos IS, Bogomolski-Yahalom V, Matzner Y: Anticardiolipin antibodies in acute myeloid leukemia: Prevalence and clinical significance. Am J Hematol 57:139-143, 1998
47. Yoon KH, Wong A, Shakespeare T, et al: High prevalence of antiphospholipid antibodies in Asian cancer patients with thrombosis. Lupus 12:112-116, 2003
48. Bacci G, Ferrari S, Bertoni F, et al: Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: Analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol 18:4-11, 2000
49. Karin M, Lawrence T, Nizet V: Innate immunity gone awry: Linking microbial infections to chronic inflammation and cancer. Cell 124:823-835, 2006
50. Sorensen HT, Mellemkjaer L, Skriver MV, et al: Fever of unknown origin and cancer: A population-based study. Lancet Oncol 6:851-855, 2005
51. Liebman HA: Current perspectives on primary prophylaxis and patient risk factors for venous thromboembolism in the cancer patient. Cancer Control 12:11-16, 2005 (suppl 1)